Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Piotr Ponikowski, Dimitrios D. Farmakis, Stefan Anker, Javed Butler, Vincent Fabien, Bridget-Anne C. Kirwan, Iain Macdougall, Marco Metra, Giuseppe Rosano, Frank Ruschitzka, Peter van der Meer, Sandra A. Waechter, Ewa Jankowska
Summary: Iron deficiency, with or without anemia, is a negative prognostic factor in heart failure. In a randomized trial, intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure hospitalization and improved quality of life in iron-deficient patients stabilized after an acute heart failure episode. Subanalyses showed that the effects of FCM did not differ based on hemoglobin levels.
Article
Medicine, General & Internal
Jin Joo Park, Minjae Yoon, Hyoung-Won Cho, Sang-Eun Lee, Jin-Oh Choi, Byung-Su Yoo, Seok-Min Kang, Dong-Ju Choi
Summary: This study conducted in Korean patients with heart failure revealed a high prevalence of iron deficiency, especially in women. Clinical parameters are not sufficient to diagnose iron deficiency, and routine laboratory examinations are necessary to identify affected patients.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Review
Cardiac & Cardiovascular Systems
Caterina Rizzo, Rosa Carbonara, Roberta Ruggieri, Andrea Passantino, Domenico Scrutinio
Summary: Iron deficiency is a common comorbidity in patients with heart failure and can greatly affect quality of life and prognosis. Treatment guidelines recommend initiating iron replacement therapy based on specific blood markers to improve symptoms and exercise capacity.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Medicine, General & Internal
Hidekatsu Fukuta, Hiromi Hagiwara, Takeshi Kamiya
Summary: This meta-analysis aims to evaluate the effect of iron therapy on exercise capacity, HF symptoms, and health-related quality of life in iron-deficiency HFpEF patients, providing evidence for iron administration in this population.
Article
Hematology
Ronak H. Mistry, Andrew Kohut, Patricia Ford
Summary: Iron deficiency in heart failure patients is associated with increased mortality, but diagnosing it can be challenging. While intravenous iron supplementation has been shown to be superior, diagnosing ID in hospitalized patients remains a challenge. Our study found no significant difference in readmission rates or mortality between HF patients who received IVFe treatment and those who did not.
ANNALS OF HEMATOLOGY
(2021)
Review
Medicine, General & Internal
Cristina Elena Singer, Corina Maria Vasile, Mihaela Popescu, Alin Iulian Silviu Popescu, Iulia Cristina Marginean, George Alexandru Iacob, Mihai Daniel Popescu, Cristina Maria Marginean
Summary: This review aims to explore the impact of iron deficiency on chronic heart failure patients, including the physiopathological traits, clinical features, and the correlation between functional and absolute iron deficiency with heart failure. Recent studies have shown that intravenous iron therapy is the only viable treatment option for iron deficiency and systolic heart failure patients, with beneficial effects on quality of life and exercise capacity.
Review
Cardiac & Cardiovascular Systems
Stormi E. E. Gale, Bobbie Nguyen, Steven P. P. Dunn, Erik Kellison, Emily F. F. Gorman, Craig Beavers
Summary: Iron deficiency is common and associated with worse outcomes in heart failure patients. Intravenous iron supplementation shows promise in improving exercise capacity, quality of life, and hospitalizations, while the benefits of oral iron remain uncertain.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Pardeep S. Jhund, Mark C. Petrie, Michele Robertson, Patrick B. Mark, Michael R. MacDonald, Eugene Connolly, Stefan D. Anker, Sunil Bhandari, Kenneth Farrington, Philip A. Kalra, David C. Wheeler, Charles R. V. Tomson, Ian Ford, John J. V. McMurray, Iain C. Macdougall
Summary: High-dose intravenous iron was found to decrease the occurrence of first and recurrent heart failure events in hemodialysis patients compared to a lower-dose regimen, with significant relative and absolute risk reductions. History of heart failure and diabetes were identified as independent predictors of a heart failure event.
JACC-HEART FAILURE
(2021)
Review
Urology & Nephrology
Jay B. Wish, Stefan D. Anker, Javed Butler, Aleix Cases, Austin G. Stack, Iain C. Macdougall
Summary: The physiological role of iron extends well beyond hematopoiesis, and iron deficiency has effects beyond anemia. Despite the close relationship between iron deficiency and CKD anemia, they are distinct clinical entities, with nephrologists focusing primarily on correcting anemia, particularly in HF patients. Correction of iron deficiency in HF patients can improve functional status and quality of life, underscoring the importance of considering iron therapy in CKD patients.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Justin A. Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, Vojtech Melenovsky, Jorge Escobedo, Javed Butler, Adrian F. Hernandez, Carolyn S. P. Lam, Christopher M. O'Connor, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Christopher deFilippi, Cynthia M. Westerhout, Ciaran McMullan, Lothar Roessig, Paul W. Armstrong
Summary: In the VICTORIA trial, anemia was more common in patients treated with vericiguat compared to placebo. While lower hemoglobin levels were associated with more clinical events, the treatment benefit of vericiguat was not affected by changes in hemoglobin levels over time.
Article
Cardiac & Cardiovascular Systems
Aleksandra Paterek, Marta Okninska, Ewelina Chajduk, Halina Polkowska-Motrenko, Michal Maczewski, Urszula Mackiewicz
Summary: The study found that systemic iron deficiency does not lead to cardiac iron deficiency or affect the progression of chronic heart failure, but instead may improve contractile function and calcium handling of isolated left ventricular cardiomyocytes, although at the expense of increased catecholamine levels. Consequently, intravenous iron therapy could be considered as an additional therapeutic option in heart failure to prevent the adverse effects of increased catecholamine levels in the long term.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Akira Sezai, Hisakuni Sekino, Makoto Taoka, Shunji Osaka, Masashi Tanaka
Summary: Erythropoiesis-stimulating agents, specifically continuous erythropoietin receptor activator (CERA), have shown positive effects on heart failure with renal anemia by improving NYHA functional class and reducing hospital readmission rates. This prospective study investigated the impact of CERA on cardiac, renal function, and oxidative stress. The results demonstrate that CERA effectively improves anemia, reduces renal impairment, and alleviates cardiac and oxidative stress. The findings of this study are relevant for investigating the switch from CERA to a new drug for renal anemia, such as a hypoxia-inducible factor prolyl-hydroxylase inhibitor.
Article
Cardiac & Cardiovascular Systems
Piotr Ponikowski, Robert J. Mentz, Adrian F. Hernandez, Javed Butler, Muhammad Shahzeb Khan, Dirk J. van Veldhuisen, Bernard Roubert, Nicole Blackman, Tim Friede, Ewa A. Jankowska, Stefan D. Anker
Summary: This meta-analysis of intravenous ferric carboxymaltose therapy for iron-deficient heart failure patients found a significantly reduced risk of hospitalizations for HF and cardiovascular causes, with no apparent effect on mortality.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Kieran F. Docherty, Paul Welsh, Subodh Verma, Rudolf A. De Boer, Eileen O'Meara, Olof Bengtsson, Lars Kober, Mikhail N. Kosiborod, Ann Hammarstedt, Anna Maria Langkilde, Daniel Lindholm, Dustin J. Little, Mikaela Sjostrand, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, David A. Morrow, Morten Schou, Scott D. Solomon, Naveed Sattar, Pardeep S. Jhund, John J. McMurray
Summary: This study examined the prevalence and consequences of iron deficiency in heart failure patients and found that it was associated with worse outcomes. Dapagliflozin had an effect on markers of iron metabolism and improved outcomes regardless of iron status at baseline.
Article
Cardiac & Cardiovascular Systems
Gabriele Masini, Fraser J. Graham, Pierpaolo Pellicori, John G. F. Cleland, Joseph J. Cuthbert, Syed Kazmi, Riccardo M. Inciardi, Andrew L. Clark
Summary: Different definitions of iron deficiency (ID) lead to inconsistent prevalence and prognosis. Definitions lacking specificity may attenuate the benefits of intravenous iron therapy, while definitions lacking sensitivity may exclude patients who should receive intravenous iron therapy.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
